Cefaclor Adverse Drug Reactions in a Tertiary Hospital in Korea

Hyo-In Rhyou1,2, Hee-Joo Nam2, Young-Hee Nam1,2*

1 Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea
2 Dong-A University Hospital Regional Pharmacovigilance Center, Busan, Korea

Background

- Cefaclor, a second-generation oral cephalosporin, is widely prescribed for infectious diseases.
- The use of cefaclor is gradually increasing, and the number of cases of adverse drug reaction (ADR) related cefaclor has been reported to increase.

However, there are few studies on ADR of cefaclor in Korea.

Methods

- Patients with cefaclor or other cephalosporin ADRs who were reported to the regional pharmacovigilance center in Dong-A university hospital from 2014 to 2018 were collected. ADR cases with possible, probable, or certain by WHO-UMC criteria were analyzed.
- We evaluated the incidence rate of cefaclor and other cephalosporin ADRs in our hospital.
- We analyzed clinical features of cefaclor ADRs according to the type and severity, and compared to other cephalosporin ADRs.

Objective

- We analyzed cefaclor ADRs in a tertiary hospital in Korea.

Result

Table I. Characteristics of patients with cefaclor ADR

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>n=150</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>48.03 ± 16.009*</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>95 (63.8)</td>
</tr>
<tr>
<td>Allergic diseases, n (%)</td>
<td>31 (20.8)</td>
</tr>
<tr>
<td>Previous history of ADR, n (%)</td>
<td>71 (47.7)</td>
</tr>
</tbody>
</table>

* presented with mean value ± standard deviation

Conclusion

- Most cefaclor ADRs were occurred at other medical institutions, mostly primary care units.
- The incidence rate of cefaclor was not high when compared with other oral cephalosporin antibiotics in our hospital.
- However, proportions of type B and anaphylaxis were identified much higher in cefaclor ADRs than in other cephalosporin ADRs.
- Large-scaled studies and a management plan for cefaclor ADRs are needed in the future.

This study was supported by a grant from Ministry of food and Drug Safety to operation of the regional pharmacovigilance center in 2020.